These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24291998)

  • 1. [Gastrointestinal dysfunction has important implications for plasma L-dopa concentrations in Parkinson's disease].
    Doi H; Sakakibara R; Kishi M; Tsuyuzaki Y; Tateno F; Hirai S
    Rinsho Shinkeigaku; 2013; 53(11):1382-5. PubMed ID: 24291998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a difference in gastric emptying between Parkinson's disease patients under long-term L-dopa therapy with and without motor fluctuations? An analysis using the 13C-acetate breath test.
    Tanaka Y; Kato T; Nishida H; Araki H; Murase M; Nagaki M; Moriwaki H; Inuzuka T
    J Neurol; 2009 Dec; 256(12):1972-6. PubMed ID: 19575260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastric emptying time and gastric motility in patients with Parkinson's disease.
    Hardoff R; Sula M; Tamir A; Soil A; Front A; Badarna S; Honigman S; Giladi N
    Mov Disord; 2001 Nov; 16(6):1041-7. PubMed ID: 11748735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed Gastric Emptying in Advanced Parkinson Disease: Correlation With Therapeutic Doses.
    Bestetti A; Capozza A; Lacerenza M; Manfredi L; Mancini F
    Clin Nucl Med; 2017 Feb; 42(2):83-87. PubMed ID: 27941374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease.
    Asai H; Udaka F; Hirano M; Minami T; Oda M; Kubori T; Nishinaka K; Kameyama M; Ueno S
    Parkinsonism Relat Disord; 2005 Dec; 11(8):499-502. PubMed ID: 16263322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
    Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
    Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa delivery systems: advancements in delivery of the gold standard.
    Ngwuluka N; Pillay V; Du Toit LC; Ndesendo V; Choonara Y; Modi G; Naidoo D
    Expert Opin Drug Deliv; 2010 Feb; 7(2):203-24. PubMed ID: 20095943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irregular gastrointestinal drug absorption in Parkinson's disease.
    Nyholm D; Lennernäs H
    Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):193-203. PubMed ID: 18248312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of gastric complications on levodopa treatment in Parkinson's disease.
    Pfeiffer RF; Isaacson SH; Pahwa R
    Parkinsonism Relat Disord; 2020 Jul; 76():63-71. PubMed ID: 32461054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease.
    Simms SL; Huettner DP; Kortagere S
    Neuropharmacology; 2016 Jan; 100():106-15. PubMed ID: 25896768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.
    Napolitano A; Del Dotto P; Petrozzi L; Dell'Agnello G; Bellini G; Gambaccini G; Bonuccelli U
    Clin Neuropharmacol; 1999; 22(1):24-9. PubMed ID: 10047930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.
    Müller T; Kuhn W
    Mov Disord; 2009 Jul; 24(9):1339-43. PubMed ID: 19425084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease.
    Doi H; Sakakibara R; Sato M; Masaka T; Kishi M; Tateno A; Tateno F; Tsuyusaki Y; Takahashi O
    J Neurol Sci; 2012 Aug; 319(1-2):86-8. PubMed ID: 22632782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DA-9701 on gastric motility in patients with Parkinson's disease: A randomized controlled trial.
    Shin CM; Lee YJ; Kim JM; Lee JY; Kim KJ; Choi YJ; Kim N; Lee DH
    Parkinsonism Relat Disord; 2018 Sep; 54():84-89. PubMed ID: 29705555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring in Parkinson's disease.
    Müller T; Gerlach M; Hefner G; Hiemke C; Jost WH; Riederer P
    J Neural Transm (Vienna); 2024 Oct; 131(10):1247-1262. PubMed ID: 39227478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosensor Strip for Rapid On-site Assessment of Levodopa Pharmacokinetics along with Motor Performance in Parkinson's Disease.
    Mahato K; Moon JM; Moonla C; Longardner K; Ghodsi H; Litvan I; Wang J
    Angew Chem Int Ed Engl; 2024 Jul; 63(27):e202403583. PubMed ID: 38682251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed gastric emptying in Parkinson's disease.
    Marrinan S; Emmanuel AV; Burn DJ
    Mov Disord; 2014 Jan; 29(1):23-32. PubMed ID: 24151126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-duration action of levodopa may be due to a postsynaptic effect.
    Barbato L; Stocchi F; Monge A; Vacca L; Ruggieri S; Nordera G; Marsden CD
    Clin Neuropharmacol; 1997 Oct; 20(5):394-401. PubMed ID: 9331515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients.
    Pierantozzi M; Pietroiusti A; Sancesario G; Lunardi G; Fedele E; Giacomini P; Frasca S; Galante A; Marciani MG; Stanzione P
    Neurol Sci; 2001 Feb; 22(1):89-91. PubMed ID: 11487216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.